http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Yung-Chung Chen (검색결과 19 건)
- 무료
- 기관 내 무료
- 유료
-
Reliability Models for Application Software in Maintenance Phase
Chen, Yung-Chung,Tsai, Shih-Ying,Chen, Peter Korean Institute of Industrial Engineers 2008 Industrial Engineeering & Management Systems Vol.7 No.1
With growing demand for zero defects, predicting reliability of software systems is gaining importance. Software reliability models are used to estimate the reliability or the number of latent defects in a software product. Most reliability models to estimate the reliability of software in the literature are based on the development lifecycle stages. However, in the maintenance phase, the software needs to be corrected for errors and to be enhanced for the requests from users. These decrease the reliability of software. Software Reliability Growth Models (SRGMs) have been applied successfully to model software reliability in development phase. The software reliability in maintenance phase exhibits many types of systematic or irregular behaviors. These may include cyclic behavior as well as long-term evolutionary trends. The cyclic behavior may involve multiple periodicities and may be asymmetric in nature. In this paper, SGRM has been adapted to develop a reliability prediction model for the software in maintenance phase. The model is established using maintenance data from a commercial shop floor control system. The model is accepted to be used for resource planning and assuring the quality of the maintenance work to the user.
-
Yung-Chung Chen,Yu-Yang Su,Sheng-Huei Hsiao 한국섬유공학회 2019 Fibers and polymers Vol.20 No.9
A series of fluorinated poly(ether imide)s (PEIs) were prepared from asymmetry, bulky featured of 1,2-bis(3,4-dicarboxyphenoxy)-4-tert-butylbenzene dianhydride and various trifluoromethyl-based bis(ether amine)s via conventionalthermal (H) or chemical (C) imidization. All fluorinated PEIs exhibited flexible, good mechanical properties and excellentsolubility in a variety of organic solvents. In addition, the chemical imidization based PEI thin films showed cut-offwavelengths of UV-vis absorptions below 380 nm with very low yellowness index (b* < 5.5). They also exhibited highthermal stability with the 10 % weight loss temperature from 486 to 550 oC of in nitrogen or air atmosphere. Compared withthe corresponding PEIs based on non-fluorinated bis(ether amine)s, fluorinated PEIs not only showed higher opticaltransparency, lower dielectric constants and water absorptions but also maintained thermal and mechanical properties.
-
Reliability Models for Application Software in Maintenance Phase
Yung-Chung Chen,Shih-Ying Tsai,Peter Chen 대한산업공학회 2008 Industrial Engineeering & Management Systems Vol.7 No.1
With growing demand for zero defects, predicting reliability of software systems is gaining importance. Software reliability models are used to estimate the reliability or the number of latent defects in a software product. Most reliability models to estimate the reliability of software in the literature are based on the development lifecycle stages. However, in the maintenance phase, the software needs to be corrected for errors and to be enhanced for the requests from users. These decrease the reliability of software. Software Reliability Growth Models (SRGMs) have been applied successfully to model software reliability in development phase. The software reliability in maintenance phase exhibits many types of systematic or irregular behaviors. These may include cyclic behavior as well as long-term evolutionary trends. The cyclic behavior may involve multiple periodicities and may be asymmetric in nature. In this paper, SGRM has been adapted to develop a reliability prediction model for the software in maintenance phase. The model is established using maintenance data from a commercial shop floor control system. The model is accepted to be used for resource planning and assuring the quality of the maintenance work to the user.
-
Chen, Jen-Shi,Chao, Yee,Bang, Yung-Jue,Roca, Enrique,Chung, Hyun C.,Palazzo, Felipe,Kim, Yeul H.,Myrand, Scott P.,Mullaney, Brian P.,Shen, Li J.,Linn, Carlos Lippincott Williams Wilkins, Inc. 2010 ANTICANCER DRUGS Vol.21 No.8
This phase I/II study was conducted to determine the maximum recommended dose of pemetrexed when given in combination with a fixed dose of cisplatin, and the efficacy, toxicity and association of 5,10-methylenetetrahydrofolate reductase (MTHFR) variants with this pemetrexed--cisplatin combination, in patients with unresectable, advanced gastric carcinoma. Patients 18–70 years of age, with stage IV disease or post-surgery recurrence, no earlier palliative chemotherapy, 0 or 1 Eastern Cooperative Oncology Group performance status, were included. The cisplatin dose was 75 mg/m. In phase I, the initial dose of pemetrexed was 600 mg/m, escalated in 100 mg/m increments. In phase II, efficacy, including overall response rate, overall survival, as well as toxicity and MTHFR pharmacogenetics were investigated. Phase I enrolled 16 patients; 700 mg/m was defined as pemetrexed recommended dose. Thirteen serious adverse events were reported; the most common grade 3/4 toxicities were haematologic (10 of 13, 76.9%). Phase II enrolled 73 patients, 69 qualified for safety and 68 for efficacy analysis; 65 for pharmacogenomic analysis. Overall response rate was 23.5% (14.1%, 35.4%), disease control rate 55.9%, median overall survival 11.8 months (95% confidence interval, 7.2–18.5 months), progression-free survival 4.9 months (95% confidence interval, 2.8–7.1 months), and median response duration 5.4 months. Patients with MTHFR A1298C variants had median overall survival of 6.6 months, significantly shorter than patients with the wild type (median 18.5 months, P=0.001). The pemetrexed--cisplatin combination in patients with advanced gastric cancer generates modest efficacy and a manageable toxicity profile. The reduced overall survival in patients with MTHFR A1298C polymorphism variants deserves further investigation.
-
Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Bang, Yung-Jue,Kang, Yoon-Koo,Kang, Won K.,Boku, Narikazu,Chung, Hyun C.,Chen, Jen-Shi,Doi, Toshihiko,Sun, Yan,Shen, Lin,Qin, Shukui,Ng, Wai-Tong,Tursi, Jennifer M.,Lechuga, Maria J.,Lu, Dongrui Ray,R Springer US 2011 Investigational new drugs Vol.29 No.6
<P><B>Summary</B></P><P><I>Purpose.</I> This phase II, open-label, multicenter study assessed the oral, multitargeted, tyrosine kinase inhibitor sunitinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma who had received prior chemotherapy. <I>Experimental design</I>. Patients received sunitinib 50 mg/day on Schedule 4/2 (4 weeks on treatment, followed by 2 weeks off treatment). The primary endpoint was objective response rate; secondary endpoints included clinical benefit rate, duration of response, progression-free survival (PFS), overall survival (OS), pharmacokinetics, pharmacodynamics, safety and tolerability, and quality of life. <I>Results</I>. Of 78 patients enrolled, most had gastric adenocarcinoma (93.6%) and metastatic disease (93.6%). All were evaluable for safety and efficacy. Two patients (2.6%) had partial responses and 25 patients (32.1%) had a best response of stable disease for ≥6 weeks. Median PFS was 2.3 months (95% confidence interval [CI], 1.6–2.6 months) and median OS was 6.8 months (95% CI, 4.4–9.6 months). Grade ≥3 thrombocytopenia and neutropenia were reported in 34.6% and 29.4% of patients, respectively, and the most common non-hematologic adverse events were fatigue, anorexia, nausea, diarrhea, and stomatitis. Pharmacokinetics of sunitinib and its active metabolite were consistent with previous reports. There were no marked associations between baseline soluble protein levels, or changes from baseline, and measures of clinical outcome. <I>Conclusions</I>. The progression-delaying effect and manageable toxicity observed with sunitinib in this study suggest that although single-agent sunitinib has insufficient clinical value as second-line treatment for advanced gastric cancer, its role in combination with chemotherapy merits further study.</P>
-
Angela Yung-Chi Hou,Robert Morse,Chung-Lin Chiang,Hui-Jung Chen 서울대학교 교육연구소 2013 Asia Pacific Education Review Vol.14 No.3
As the numbers of international students have grown, higher education institutions in Asia have offered a growing range of English medium instruction (EMI) degree programs. But Asian governments and higher education institutions have not thought deeply about how to ensure quality of English medium instruction degree programs. At the same time, their accreditors have not been fully aware of how to establish an external quality assurance mechanism to measure the quality of these programs. This study’s main purpose is to put the quality of the EMI degree programs of Taiwan higher education institutions into the perspective of the Taiwan’s institutions and one local Taiwan accreditor. With both qualitative and quantitative approaches, a survey targeting Taiwan’s colleges and universities and interviews of Higher Education Evaluation & Accreditation Council of Taiwan international reviewers and Asian higher education experts are used to examine the challenges of EMI implementation in Taiwan universities and the role of local accreditors playing in reviewing the English medium instruction degree programs.
-
-
Zhongkai Chen,Daniel Hsiang-Yung Teng,Gary Chung-Jhih Wang,Shih-Kang Fan 한국바이오칩학회 2011 BioChip Journal Vol.5 No.4
Droplet-based digital microfluidic lab-onchips exploiting electrowetting-on-dielectric (EWOD) have been studied over the last decade. With the recent introduction of new highly scalable, reconfigurable and field-programmable microelectrode dot array (MEDA) architecture, there is a compelling need for a new digital microfluidics synthesizer for the new MEDA architecture. Droplet routing is a critical part of the digital microfluidics synthesizer. This paper presents a routing algorithm and the associated performance analysis results. The algorithm is able to route different sizes of reagent and sample droplets simultaneously and also incorporates other characteristics such as diagonal movements and channel-based movements that are specific to the MEDA architecture.
-
Fa-Po Chung,Chin-Yu Lin,Yenn-Jiang Lin,Shih-Lin Chang,Li-Wei Lo,Yu-Feng Hu,Ta-Chuan Tuan,Tze-Fan Chao,Jo-Nan Liao,Ting-Yung Chang,Shih-Ann Chen 대한심장학회 2018 Korean Circulation Journal Vol.48 No.10
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is predominantly an inherited cardiomyopathy with typical histopathological characteristics of fibro-fatty infiltration mainly involving the right ventricular (RV) inflow tract, RV outflow tract, and RV apex in the majority of patients. The above pathologic evolution frequently brings patients with ARVD/C to medical attention owing to the manifestation of syncope, sudden cardiac death (SCD), ventricular arrhythmogenesis, or heart failure. To prevent future or recurrent SCD, an implantable cardiac defibrillator (ICD) is highly desirable in patients with ARVD/C who had experienced unexplained syncope, hemodynamically intolerable ventricular tachycardia (VT), ventricular fibrillation, and/or aborted SCD. Notably, the management of frequent ventricular tachyarrhythmias in ARVD/C is challenging, and the use of antiarrhythmic drugs could be unsatisfactory or limited by the unfavorable side effects. Therefore, radiofrequency catheter ablation (RFCA) has been implemented to treat the drug-refractory VT in ARVD/C for decades. However, the initial understanding of the link between fibro-fatty pathogenesis and ventricular arrhythmogenesis in ARVD/C is scarce, the efficacy and prognosis of endocardial RFCA alone were limited and disappointing. The electrophysiologists had broken through this frontier after better illustration of epicardial substrates and broadly application of epicardial approaches in ARVD/C. In recent works of literature, the application of epicardial ablation also successfully results in higher procedural success and decreases VT recurrences in patients with ARVD/C who are refractory to the endocardial approach during long-term follow-up. In this article, we review the important evolution on the delineation of arrhythmogenic substrates, ablation strategies, and ablation outcome of VT in patients with ARVD/C.
-
Yen-Yang Chen,Chen-Chi Wang,Ying-Cheng Lin,John Y Kao,Chun-Yi Chuang,Yung-An Tsou,Ja-Chih Fu,Sheng-Shun Yang,Chi-Sen Chang,Han-Chung Lien 대한소화기 기능성질환∙운동학회 2023 Journal of Neurogastroenterology and Motility (JNM Vol.29 No.1
Background/AimsHypopharyngeal multichannel intraluminal impedance-pH (HMII-pH) technology incorporating 2 trans-upper esophageal sphincter impedance channels has been developed to detect pharyngeal reflux. We used the HMII-pH technique to validate the candidate pharyngeal acid reflux (PAR) episodes based on the dual-pH tracings and determined the interobserver reproducibility. MethodsWe conducted a cross-sectional study in tertiary centers in Taiwan. Ninety patients with suspected laryngopharyngeal reflux and 28 healthy volunteers underwent HMII-pH test when off acid suppressants. Candidate PAR episodes were characterized by pharyngeal pH drops of at least 2 units and reaching a nadir pH of 5 within 30 seconds during esophageal acidification. Two experts manually independently identified candidate PAR episodes based on the dual-pH tracings. By reviewing the HMII-pH tracings, HMII-pH-proven PAR episodes were subsequently confirmed. The consensus reviews of HMII-pH-proven PAR episodes were considered to be the reference standard diagnosis. The interobserver reproducibility was assessed. ResultsA total of 105 candidate PAR episodes were identified. Among them 84 (80.0%; 95% CI, 71.0-87.0%) were HMII-pH-proven PAR episodes (82 in 16 patients and 2 in 1 healthy subject). Patients tended to have more HMII-pH-proven PAR episodes than healthy controls (median and percentile values [25th, 75th, and 95th percentiles]: 0 [0, 0, 3] vs 0 [0, 0, 0], P = 0.067). The concordance rate in diagnosing HMII-pH-proven PAR episodes between 2 independent observers was 92.2%. ConclusionOur preliminary data showed that 80.0% (71.0-87.0%) of the proposed candidate PAR episodes were HMII-pH-proven PAR episodes, among which the interobserver reproducibility was good.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
